4'-(4-pentylcyclohexyl)biphenyl-4-carboxylic acid | 306962-82-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-(4-pentylcyclohexyl)biphenyl-4-carboxylic acid
• 英文别名: 4-[4-(4-pentylcyclohexyl)phenyl]benzoic acid
• CAS: 306962-82-3
• 化学式: C₂₄H₃₀O₂
• 分子量: 350.501
• InChiKey: HMEOOKGLYKYTGR-UHFFFAOYSA-N

物化性质

• 熔点：
  248-251 °C (decomp)
• 沸点：
  505.7±39.0 °C(Predicted)
• 密度：
  1.044±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4'-(4-pentylcyclohexyl)biphenyl-4-carboxylic acid 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以92%的产率得到4'-(trans-4-Pentylcyclohexyl)-4-biphenylcarboxylic acid chloride
  参考文献：
  名称：

  Griesar; Soto-Bustamante; Haase, Zeitschrift fur Naturforschung, B: Chemical Sciences, 2000, vol. 55, # 7, p. 567 - 575

  摘要：

  DOI：
• 作为产物：
  描述：

  4-cyano-4'-(trans-4-pentylcyclohexyl)-1,1'-biphenyl 在 氢氧化钾 作用下， 以 二乙二醇 为溶剂， 反应 12.0h， 以81%的产率得到4'-(4-pentylcyclohexyl)biphenyl-4-carboxylic acid
  参考文献：
  名称：

  Griesar; Soto-Bustamante; Haase, Zeitschrift fur Naturforschung, B: Chemical Sciences, 2000, vol. 55, # 7, p. 567 - 575

  摘要：

  DOI：

文献信息

• ULTRAVIOLET LIGHT ABSORBERS
  申请人：Transitions Optical, Inc.

  公开号：US20170275534A1

  公开（公告）日：2017-09-28

  The present invention relates to compounds that have ultraviolet light absorbing properties, and which can also have mesogenic properties. The present invention also relates to compositions that include one or more such compounds, and to articles of manufacture that include one or more such compounds, such as optical elements that include an optical substrate and a layer that includes at least one compound of the present invention.

  本发明涉及具有吸收紫外光特性的化合物，该化合物还可以具有介向性质。本发明还涉及包括一种或多种这种化合物的组合物，以及包括一种或多种这种化合物的制造物，例如包括光学基底和包含本发明至少一种化合物的层的光学元件。
• COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS
  申请人：Olsson Roger

  公开号：US20090176837A1

  公开（公告）日：2009-07-09

  Disclosed herein are novel compounds with activity at RARβ 2 receptors. Further disclosed are the use of such compounds for treatment of or to alleviate symptoms of cancer, neurological disorders such as memory deficits and schizophrenia, neurodegenerative disorders such as Parkinson's and Alzheimer's diseases, inflammatory disorders such as psoriasis and rheumatoid arthritis, eye disorders and depression.

  本文揭示了具有对RARβ 2受体活性的新化合物。进一步揭示了这些化合物的用途，用于治疗或缓解癌症、神经系统疾病（如记忆障碍和精神分裂症）、神经退行性疾病（如帕金森病和阿尔茨海默病）、炎症性疾病（如银屑病和类风湿性关节炎）、眼部疾病和抑郁症状。
• Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions
  申请人：HITACHI, LTD.

  公开号：EP0341713A2

  公开（公告）日：1989-11-15

  The invention relates to optically active compounds represented by the general formula I wherein m, n, Ri, R2, R3. R4, Q1, Q2, Q3, and M are defined as in the specification, methods and intermediates for their preparation, liquid crystal compositions comprising at least one optically active compound of formula I and their use in electrooptical display, switching and modulation devices.

  本发明涉及通式 I 所代表的光学活性化合物 其中m、n、Ri、R2、R3.R4、Q1、Q2、Q3 和 M 在说明书中的定义、制备它们的方法和中间体、包含至少一种式 I 的光学活性化合物的液晶组合物以及它们在光电显示、开关和调制装置中的用途。
• Ultraviolet light absorbers
  申请人：Transitions Optical, Inc.

  公开号：US10619098B2

  公开（公告）日：2020-04-14

  Compounds that have ultraviolet light absorbing properties, and which can also have mesogenic properties. Compositions that include one or more such compounds. Articles of manufacture that include one or more such compounds, such as optical elements that include an optical substrate and a layer that includes at least one such compound.

  具有紫外线吸收特性的化合物，也可具有中生特性。包含一种或多种此类化合物的组合物。包括一种或多种此类化合物的制造品，如包括光学基底和至少一种此类化合物层的光学元件。
• An improved protocol for ligandless Suzuki–Miyaura coupling in water
  作者：Dmitrii N. Korolev、Nikolay A. Bumagin

  DOI：10.1016/j.tetlet.2006.04.039

  日期：2006.6

  Using a reverse order of addition of reagents, PdCl2 and Pd(OAc)(2) are efficient catalysts for the Suzuki-Miyaura reactions in water. The ligandless and mild conditions, the high stability of the catalytic system, short reaction time and good to excellent yields are important features of this protocol. (c) 2006 Published by Elsevier Ltd.